Abstract 2507
Background
In mCRPC pts unselected for homologous recombination deficiency (HRD), promising activity was seen with combination programmed death 1 inhibitor pembro and OLA in the phase 1b/2 KEYNOTE-365 study (NCT02861573), warranting further investigation in this population. KEYLYNK-010 (NCT03834519) is a phase 3, randomized, open-label trial to evaluate efficacy and safety of pembro plus OLA in molecularly unselected ENZA- or ABI-pretreated pts with mCRPC whose disease progressed with CTx.
Trial design
Eligible pts (≥18 years) must have histologically confirmed mCRPC and prior treatment (tx) with ABI or ENZA (but not both) and prior tx with CTx (1 prior docetaxel-based regimen). Pts must have an ECOG PS of 0/1, adequate organ function, and tumor tissue for biomarker analysis. Pts will be randomly assigned 2:1 to receive pembro 200 mg intravenously Q3W plus OLA 300 mg orally twice daily or ABI 1000 mg orally once daily plus prednisone/prednisolone 5 mg orally twice daily (for ENZA-pretreated pts) or ENZA 160 mg/day orally (for ABI-pretreated pts). Arms will be stratified per prior tx (ABI/ENZA) and presence of measurable disease (yes/no). Responses will be assessed by CT/MRI and radionuclide bone imaging per PCWG-modified RECIST v1.1 by blinded independent central review (BICR) Q9W during the first year and Q12W thereafter. Tx will continue with up to 2 years of pembro (35 cycles) and OLA or ABI/ENZA until radiographic disease progression, unacceptable toxicity, or consent withdrawal. Primary end points are overall survival and radiographic progression-free survival. The key secondary efficacy end point is time to initiation of subsequent anticancer therapy or death. Other secondary end points are objective response rate and duration of response per PCWG-modified RECIST v1.1 by BICR, time to first symptomatic skeletal event, and safety and tolerability. Prognostic or predictive molecular biomarkers (eg, genomic HRD status) will be explored. Approximately 780 pts will be enrolled.
Clinical trial identification
NCT03834519; February 8, 2019.
Editorial acknowledgement
Medical writing and/or editorial assistance was provided by Matt Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
E. Yu: Advisory / Consultancy: Merck, Bayer, Amgen, Pharmacyclics, Seattle Genetics; Research grant / Funding (self): Merck, Agensys, Dendreon, Seattle Genetics, Taiho, Daiichi-Sankyo; Travel / Accommodation / Expenses: Merck, Bayer, Amgen, Pharmacyclics, Seattle Genetics. J. Kim: Full / Part-time employment: Merck & Co., Inc.; Shareholder / Stockholder / Stock options: Merck & Co., Inc. E.S. Antonarakis: Honoraria (self), Research grant / Funding (self): Janssen, Sanofi, Dendreon, AstraZeneca, Clovis, Merck; Advisory / Consultancy: Astellas, Medivation, ESSA, Eli Lilly; Research grant / Funding (self): Johnson & Johnson, Genentech, Novartis, BMS; Non-remunerated activity/ies, Patent holder: Qiagen. All other authors have declared no conflicts of interest.
Resources from the same session
1122 - Platelets from metastatic cancer patients have increased aggregation and activation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
2671 - Luminal B breast cancer prognosis prediction by comprehensive analysis of Homeobox genes
Presenter: Ayako Nakashoji
Session: Poster Display session 3
Resources:
Abstract
2650 - Long non-coding RNA E2F4as promotes tumor progression and predicts patient prognosis in human ovarian cancer
Presenter: Sun-Ae Park
Session: Poster Display session 3
Resources:
Abstract
1462 - FGF19 promotes esophageal squamous cell carcinoma progression by inhibiting autophagy
Presenter: Lisha Ying
Session: Poster Display session 3
Resources:
Abstract
5787 - Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments.
Presenter: Raimondo Di Liello
Session: Poster Display session 3
Resources:
Abstract
5253 - Circulating microRNAs related to DNA damage response as predictors of survival in metastatic non- small cell lung cancer patients treated with platinum-based chemotherapy
Presenter: Dimitris Mavroudis
Session: Poster Display session 3
Resources:
Abstract
5286 - Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy
Presenter: Silvia Calabuig-Fariñas
Session: Poster Display session 3
Resources:
Abstract
5781 - Exosomes in NSCLC as a source of biomarkers
Presenter: Elena Duréndez
Session: Poster Display session 3
Resources:
Abstract
1447 - The role of Pim-1 in the development and progression of papillary thyroid carcinoma
Presenter: Xin Zhu
Session: Poster Display session 3
Resources:
Abstract
1323 - Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 3
Resources:
Abstract